🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Great coverage in The Pharma Letter about a major milestone for Dewpoint – the nomination of our first development candidate, DPTX3186, as a potential therapeutic agent for the treatment of Wnt-driven cancers. Read the article: thepharmaletter.com/major-mileston…

Thank you Dragomir Milovanovic for the engaging discussion about condensate biology at the synapse at our Kitchen Table Talk last week! If you missed the live event, the video recording is now available on condensates.com. condensates.com/resources/drag…

We are excited to partner with ComeInCell to support future biomedical and biotechnology researchers by providing our scientific expertise in biomolecular condensates and mentorship as they explore cellular mechanisms with advanced synthetic models. mpikg.mpg.de/6845600/launch…

We were honored to welcome our Bayer | Pharmaceuticals colleagues to Boston for engaging discussions and a tour of our state-of-the-art drug discovery facilities. We look forward to continuing to work together and apply the power of #condensate science to develop lifesaving therapeutics.

At our Harvest of Cultures event, our Boston team took time to give thanks and celebrate our diversity, families and friends, & each other! Team members shared special dishes that showcased their unique backgrounds, played games, & strengthened our amazing Dewpoint community!

Celebrating our Mitsubishi Tanabe Pharma Corporation partnership! Our condensate science expertise complements MTPC’s ALS drug development expertise to advance a small molecule c-mod that corrects an underlying pathology shared by ~97 % of ALS patients. tinyurl.com/ykx79vt7

Announcing our partnership with ConcertAI to accelerate the clinical path for DPTX3186, our 1st drug candidate for treatment of Wnt-driven cancers. This is a first step in our collaboration to support development of cmods for more 'undruggable' oncogenes. tinyurl.com/4sbv599x

Great coverage in The Pharma Letter about our partnership with ConcertAI! Read the article to learn more about the first phase of this collaboration, supporting the clinical path for DPTX3186, our first drug candidate for treatment of Wnt-driven cancers. thepharmaletter.com/dewpoint-and-c…

Join us for the first Kitchen Table Talk of 2025! Condensates.com welcomes Rui Tong Quek to the Dewpoint Kitchen Table to discuss “Advances in Targeting Biomolecular Condensates for Small Molecule Drug Discovery.” Find the login information here: tinyurl.com/7dr6ty58

We discover & develop c-mods that target the structure & function of disease-driving aberrant condensates, with the goal of exercising profound disease-modifying effects. Learn about our proprietary chemical library & our unique science-guided approach. youtu.be/ZWRcTIyvAQk

2024 was a pivotal year for Dewpoint, and we are looking forward to reaching new heights in 2025! The latest article in The Pharma Letter highlights our exciting milestones from last year and our plans for the next chapter in our evolution. thepharmaletter.com/dewpoints-big-…

At Dewpoint we transform condensate biology into medicine. Learn about the scientific foundation of our groundbreaking work youtube.com/watch?v=QxM62E…

Thank you Rui Tong Quek for kicking off our 2025 Kitchen Table Talk series with an engaging discussion! If you missed the live event, you can view the video recording on condensates.com. condensates.com/resources/rui-…

We’re proud to have our revolutionary science featured in Scientific American! Read the article, which discusses the evolution of condensate science from “mysterious blobs” to condensates’ vitally important role in cellular function. scientificamerican.com/article/myster…

To achieve our dream of transforming condensate biology into medicine, we built a state-of-the-art infrastructure that supports our innovative condensate target and drug discovery efforts, at every step. Learn more:  youtu.be/d-jp_Rb5M94

Meet the Dewpoint team at #SLAS2025! Learn about our digitally integrated, high-throughput screening and optimization platform, and how we apply it to advance revolutionary programs in the #neurodegeneration and #oncology therapeutic areas. Bede Portz

We discover #cmods using industrial-scale screening of condensate phenotypes. Our digitally integrated experimental infrastructure, powered by our AI/ML-ERSAi platform, manages, processes & analyzes data produced during screening & optimization. Learn more youtu.be/5uF1V7a7O3E

Announcing the nomination of DPTX3496, the second #cmod development candidate that targets the oncogenic driver function of beta catenin in Wnt-driven cancers. IND-enabling studies are progressing and IND filing is planned for the second half of the year. tinyurl.com/26xde734

At Dewpoint, we built a flexible integrated platform to enable a broad range of assay types & custom workflows, from target discovery & validation to drug discovery & development. See how we deploy our platform to support programs across many disease areas youtu.be/JxG8UD7jEq8